echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Tetrabenazine tablets are approved soon for the treatment of Huntington's disease

    Tetrabenazine tablets are approved soon for the treatment of Huntington's disease

    • Last Update: 2021-06-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, Shandong Bausch & Lomb Furuida Pharmaceutical Co.
    , Ltd.
    has entered the administrative stage for the import application of the 5.
    1 new drug tetrabenazine tablets (the relevant acceptance number is JXHS2000123/124), and it is expected to be officially approved soon and become the second domestic approval.
    Huntington's disease (HD) treatment drugs
    .

    Tetrabenazine (Xenazine) is a vesicle monoamine transporter 2 (VMAT2) inhibitor, which reversibly inhibits VMAT2 in vivo through its dihydroxy metabolites (HTBZ) α-HTBZ and β-HTBZ.
    Role
    .


    The drug was originally used to treat schizophrenia.


    In China, tetrabenazine was included in the "List of the First Batch of Clinically Needed New Drugs Abroad" issued by CDE in 2018, and will be reported for domestic production in August 2020
    .


    Once officially approved in the future, tetrabenazine will become the second HD drug approved in China after deuterated tetrabenazine


    In addition to the above two drugs, there are currently several HD drugs under development abroad, such as Roche's tominersen (RG6042, also called RO7234292), UniQure's AMT-130, and Voyager Therapeutics' VY-HTT01


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.